EU-funded R&D project
Patient-centric clinical trial platform
EU-PEARL has the ambition of transforming the current approach of conducting single-compound clinical trials into the use of cross-company Integrated Research Platforms (IRPs), taking into consideration both patients’ interests and the opportunities from novel molecules for addressing medical needs. Patient-centric data and knowledge sharing have the potential to accelerate the development of new treatments and reduce the operational costs of clinical trials.
EU-PEARL will improve clinical effectiveness, patients’ satisfaction and societal access to timely and affordable medicines, and it will shape the clinical trials of the future. This will change the industry paradigm from competition to cooperation in four disease areas and provide the framework for designing IRPs in other disease areas. EU-PEARL will create a reusable, accessible and sustainable modular IRP for the design and execution of patient-centric, cross-company IRP in any disease area with unmet needs. This will take into account the appropriate regulatory, ethical, legal, statistical and data utilisation requirements. The IRP design will deliver trial-ready IRP networks in the four disease areas of Major Depressive Disorder, Tuberculosis, Non-Alcoholic Steatohepatitis and Neurofibromatosis. EU-PEARL receives funding from the Innovative Medicines Initiative 2 Joint Undertaking. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
i~HD leads the main governance work package of the project, and plays a leading role in ensuring the project meets its objectives. We have specific responsibilities in information governance and GDPR compliance, interoperability and data quality, platform certification, and contributes to other sustainability actions.
Fundació Hospital Universitari Vall d’Hebrón – Institut de Recerca, EATRIS ERIC, SYNAPSE Research Management Partners SL, Medizinische Universitӓt Wien, Katholieke Universiteit Leuven, King’s College London, Universita Vita-Salute San Raffaele, Erasmus Universitair Medisch Centrum Rotterdam, Ludwig-Maximilians-Universitaet München, Charité – Universitaetsmedizin Berlin, Assistance Publique – Hôpitaux de Paris, Custodix, i~HD, Berry Consultants, ECRIN European Clinical Research Infrastructure Network, European Patients’ Forum, University of Newcastle upon Tyne, EUROSCAN International Network, Paul-Ehrlich-Institut, Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel, The Chancellor, Masters and Scholars of the University of Oxford, Università degli Studi di Milano, DocuMental OÜ, The University of Manchester, Janssen Pharmaceutica, Novartis Pharma, Allergan, AstraZeneca, Novo Nordisk, Otsuka Novel Products, Pfizer, Sanofi-Aventis Research & Development, Institut de Recherches Internationales Servier, Teva Pharmaceutical Industries, Children’s Tumor Foundation, SpringWorks Therapeutics, Global Alliance for TB Drug Development